$15.80
-0.1-0.63%
At close: -
$15.25
-0.55-3.48%
After Hours: May 2, 4:00 PM EDT
Comments
Loading...
Immunovant Analyst Ratings and Price Targets | NASDAQ:IMVT | Benzinga
Immunovant Inc has a consensus price target of $37.71 based on the ratings of 20 analysts. The high is $57 issued by Piper Sandler on October 24, 2023. The low is $4 issued by Credit Suisse on May 23, 2023. The 3 most-recent analyst ratings were released by UBS, B of A Securities, and HC Wainwright & Co. on April 22, 2025, March 20, 2025, and March 19, 2025, respectively. With an average price target of $33.67 between UBS, B of A Securities, and HC Wainwright & Co., there's an implied 120.77% upside for Immunovant Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
B of A Securities
HC Wainwright & Co.
Wells Fargo
Raymond James
1calculated from analyst ratings
Analyst Ratings for Immunovant
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/22/2025 | Buy Now | 11.48% | UBS | Colin Bristow40% | $38 → $17 | Downgrade | Buy → Neutral | Get Alert |
| 03/20/2025 | Buy Now | — | Guggenheim | Yatin Suneja50% | — | Reiterates | Buy → Buy | Get Alert |
| 03/20/2025 | Buy Now | 116.39% | B of A Securities | Jason Gerberry60% | $38 → $33 | Maintains | Buy | Get Alert |
| 03/19/2025 | Buy Now | 234.43% | HC Wainwright & Co. | Douglas Tsao53% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 03/10/2025 | Buy Now | — | Guggenheim | Yatin Suneja50% | — | Reiterates | Buy → Buy | Get Alert |
| 02/10/2025 | Buy Now | 188.52% | Guggenheim | Yatin Suneja50% | $46 → $44 | Maintains | Buy | Get Alert |
| 02/10/2025 | Buy Now | 234.43% | HC Wainwright & Co. | Douglas Tsao53% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 02/07/2025 | Buy Now | 234.43% | HC Wainwright & Co. | Douglas Tsao53% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 01/15/2025 | Buy Now | 195.08% | B of A Securities | Jason Gerberry60% | $48 → $45 | Maintains | Buy | Get Alert |
| 01/03/2025 | Buy Now | — | Wolfe Research | Andy Chen43% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 12/19/2024 | Buy Now | 195.08% | Wells Fargo | Derek Archila60% | $47 → $45 | Maintains | Overweight | Get Alert |
| 11/08/2024 | Buy Now | 234.43% | HC Wainwright & Co. | Douglas Tsao53% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 10/10/2024 | Buy Now | 136.07% | Raymond James | Danielle Brill42% | → $36 | Reinstates | → Outperform | Get Alert |
| 10/09/2024 | Buy Now | 247.54% | Oppenheimer | Leland Gershell70% | $47 → $53 | Maintains | Outperform | Get Alert |
| 09/30/2024 | Buy Now | 234.43% | HC Wainwright & Co. | Douglas Tsao53% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 09/10/2024 | Buy Now | 234.43% | HC Wainwright & Co. | Douglas Tsao53% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 08/13/2024 | Buy Now | 168.85% | UBS | Colin Bristow40% | $42 → $41 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | 201.64% | JP Morgan | Brian Cheng37% | $51 → $46 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 06/18/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 06/03/2024 | Buy Now | 201.64% | Oppenheimer | Leland Gershell70% | $50 → $46 | Maintains | Outperform | Get Alert |
| 05/30/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 05/30/2024 | Buy Now | 234.43% | HC Wainwright & Co. | Douglas Tsao53% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | Buy Now | 227.87% | Oppenheimer | Leland Gershell70% | → $50 | Initiates | → Outperform | Get Alert |
| 03/25/2024 | Buy Now | 214.75% | Truist Securities | Robyn Karnauskas55% | → $48 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | Buy Now | 227.87% | Goldman Sachs | Corinne Johnson24% | → $50 | Initiates | → Buy | Get Alert |
| 02/20/2024 | Buy Now | 234.43% | JP Morgan | Brian Cheng37% | → $51 | Initiates | → Overweight | Get Alert |
| 02/15/2024 | Buy Now | 260.66% | Wolfe Research | Andy Chen43% | → $55 | Initiates | → Outperform | Get Alert |
| 12/21/2023 | Buy Now | 234.43% | B of A Securities | Jason Gerberry60% | $49 → $51 | Maintains | Buy | Get Alert |
| 12/21/2023 | Buy Now | 234.43% | HC Wainwright & Co. | Douglas Tsao53% | $47 → $51 | Maintains | Buy | Get Alert |
| 12/12/2023 | Buy Now | 227.87% | Deutsche Bank | Neena Bitritto-Garg59% | → $50 | Initiates | → Buy | Get Alert |
| 12/01/2023 | Buy Now | 267.21% | UBS | Colin Bristow40% | $55 → $56 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 214.75% | Truist Securities | Robyn Karnauskas55% | $30 → $48 | Maintains | Buy | Get Alert |
| 10/24/2023 | Buy Now | 273.77% | Piper Sandler | Yasmeen Rahimi59% | $28 → $57 | Maintains | Overweight | Get Alert |
| 10/24/2023 | Buy Now | 208.2% | HC Wainwright & Co. | Douglas Tsao53% | $29 → $47 | Maintains | Buy | Get Alert |
| 10/16/2023 | Buy Now | 195.08% | Cantor Fitzgerald | Louise Chen56% | $30 → $45 | Maintains | Overweight | Get Alert |
| 10/13/2023 | Buy Now | 260.66% | UBS | Colin Bristow40% | $18 → $55 | Upgrade | Neutral → Buy | Get Alert |
| 10/09/2023 | Buy Now | 96.72% | Cantor Fitzgerald | Louise Chen56% | → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 09/27/2023 | Buy Now | 214.75% | Wells Fargo | Derek Archila60% | $33 → $48 | Maintains | Overweight | Get Alert |
| 09/27/2023 | Buy Now | 227.87% | Citigroup | Samantha Semenkow34% | $33 → $50 | Maintains | Buy | Get Alert |
| 09/27/2023 | Buy Now | 162.3% | Raymond James | Danielle Brill42% | → $40 | Upgrade | Market Perform → Outperform | Get Alert |
| 09/26/2023 | Buy Now | 96.72% | Truist Securities | Robyn Karnauskas55% | → $30 | Reiterates | Buy → Buy | Get Alert |
| 09/22/2023 | Buy Now | 109.84% | Guggenheim | Yatin Suneja50% | → $32 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2023 | Buy Now | 96.72% | Cantor Fitzgerald | Louise Chen56% | → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 96.72% | Cantor Fitzgerald | Louise Chen56% | → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 08/16/2023 | Buy Now | 96.72% | Truist Securities | Robyn Karnauskas55% | → $30 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 90.16% | HC Wainwright & Co. | Douglas Tsao53% | → $29 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 116.39% | Citigroup | Samantha Semenkow34% | $28 → $33 | Maintains | Buy | Get Alert |
| 07/24/2023 | Buy Now | 116.39% | Wells Fargo | Derek Archila60% | $27 → $33 | Maintains | Overweight | Get Alert |
| 07/18/2023 | Buy Now | 122.95% | Stifel | Alex Thompson43% | $28 → $34 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | 90.16% | HC Wainwright & Co. | Douglas Tsao53% | $27 → $29 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | 77.05% | HC Wainwright & Co. | Douglas Tsao53% | $26 → $27 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | 83.61% | B of A Securities | Jason Gerberry60% | $26 → $28 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | 109.84% | Guggenheim | Yatin Suneja50% | $30 → $32 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -73.77% | Credit Suisse | Tiago Fauth43% | → $4 | Reiterates | → Underperform | Get Alert |
| 05/23/2023 | Buy Now | 109.84% | Chardan Capital | Matthew Barcus56% | $21 → $32 | Maintains | Buy | Get Alert |
| 05/01/2023 | Buy Now | 70.49% | B of A Securities | Jason Gerberry60% | → $26 | Initiates | → Buy | Get Alert |
| 04/25/2023 | Buy Now | 83.61% | Citigroup | Samantha Semenkow34% | → $28 | Initiates | → Buy | Get Alert |
| 03/31/2023 | Buy Now | 83.61% | Piper Sandler | Yasmeen Rahimi59% | → $28 | Initiates | → Overweight | Get Alert |
| 03/30/2023 | Buy Now | 83.61% | Stifel | Alex Thompson43% | → $28 | Initiates | → Buy | Get Alert |
| 03/20/2023 | Buy Now | 70.49% | HC Wainwright & Co. | Douglas Tsao53% | $21 → $26 | Maintains | Buy | Get Alert |
| 02/15/2023 | Buy Now | 96.72% | Cantor Fitzgerald | Louise Chen56% | → $30 | Initiates | → Overweight | Get Alert |
| 02/13/2023 | Buy Now | — | Guggenheim | Yatin Suneja50% | — | Upgrade | Neutral → Buy | Get Alert |
| 02/07/2023 | Buy Now | 37.7% | HC Wainwright & Co. | Douglas Tsao53% | $17 → $21 | Maintains | Buy | Get Alert |
| 02/06/2023 | Buy Now | 37.7% | SVB Leerink | Thomas Smith33% | $14 → $21 | Maintains | Outperform | Get Alert |
| 02/06/2023 | Buy Now | 37.7% | Chardan Capital | Matthew Barcus56% | $19 → $21 | Maintains | Buy | Get Alert |
| 01/03/2023 | Buy Now | 77.05% | Wells Fargo | Derek Archila60% | $10 → $27 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/08/2022 | Buy Now | -34.43% | Wells Fargo | Derek Archila60% | $7 → $10 | Maintains | Equal-Weight | Get Alert |
| 11/07/2022 | Buy Now | 11.48% | HC Wainwright & Co. | Douglas Tsao53% | $16 → $17 | Maintains | Buy | Get Alert |
| 11/07/2022 | Buy Now | 24.59% | Chardan Capital | Matthew Barcus56% | $12 → $19 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | -8.2% | SVB Leerink | Mike Kratky64% | $12 → $14 | Maintains | Outperform | Get Alert |
| 09/29/2022 | Buy Now | -21.31% | Chardan Capital | Matthew Barcus56% | $14 → $12 | Maintains | Buy | Get Alert |
| 09/26/2022 | Buy Now | -67.21% | UBS | Colin Bristow40% | $7 → $5 | Downgrade | Buy → Neutral | Get Alert |
FAQ
What is the target price for Immunovant (IMVT) stock?
The latest price target for Immunovant (NASDAQ:IMVT) was reported by UBS on April 22, 2025. The analyst firm set a price target for $17.00 expecting IMVT to rise to within 12 months (a possible 11.48% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunovant (IMVT)?
The latest analyst rating for Immunovant (NASDAQ:IMVT) was provided by UBS, and Immunovant downgraded their neutral rating.
When was the last upgrade for Immunovant (IMVT)?
The last upgrade for Immunovant Inc happened on October 13, 2023 when UBS raised their price target to $55. UBS previously had a neutral for Immunovant Inc.
When was the last downgrade for Immunovant (IMVT)?
The last downgrade for Immunovant Inc happened on April 22, 2025 when UBS changed their price target from $38 to $17 for Immunovant Inc.
When is the next analyst rating going to be posted or updated for Immunovant (IMVT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunovant, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunovant was filed on April 22, 2025 so you should expect the next rating to be made available sometime around April 22, 2026.
Is the Analyst Rating Immunovant (IMVT) correct?
While ratings are subjective and will change, the latest Immunovant (IMVT) rating was a downgraded with a price target of $38.00 to $17.00. The current price Immunovant (IMVT) is trading at is $15.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
